{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Simeprevir+75+mg", "query": { "intervention": "Simeprevir 75 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T01:34:46.582Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02165189", "title": "An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitits C" ], "interventions": [ { "name": "Simeprevir", "type": "DRUG" }, { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2014-08", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2016-11-11", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 11, "location_summary": "Aurora, Colorado • Gainesville, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02165189" }, { "nct_id": "NCT01466790", "title": "A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "PSI-7977 (GS7977)", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 168, "start_date": "2012-01", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-02-09", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 22, "location_summary": "Hoover, Alabama • Bakersfield, California • La Jolla, California + 19 more", "locations": [ { "city": "Hoover", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01466790" }, { "nct_id": "NCT00980330", "title": "A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peg-IFN-alfa-2a (P)", "type": "DRUG" }, { "name": "Ribavirin (R)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 463, "start_date": "2009-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 17, "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00980330" }, { "nct_id": "NCT00882908", "title": "A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Ribavirin (R)", "type": "DRUG" }, { "name": "PegIFNα-2a (P)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 386, "start_date": "2009-06", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2014-06-16", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 12, "location_summary": "Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00882908" }, { "nct_id": "NCT03059303", "title": "Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Simeprevir 75 mg", "type": "DRUG" }, { "name": "Odalasvir 25 mg", "type": "DRUG" }, { "name": "Odalasvir 12.5 mg", "type": "DRUG" }, { "name": "Odalasvir 75 mg", "type": "DRUG" }, { "name": "AL-335 800 mg", "type": "DRUG" }, { "name": "Lansoprazole 30 mg", "type": "DRUG" }, { "name": "Omeprazole 20 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 72, "start_date": "2017-02-20", "completion_date": "2017-04-24", "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03059303" }, { "nct_id": "NCT02885454", "title": "To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Drospirenone/ethinylestradiol", "type": "DRUG" }, { "name": "AL-335", "type": "DRUG" }, { "name": "Odalasvir (ODV)", "type": "DRUG" }, { "name": "Simeprevir (SMV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 24, "start_date": "2016-08", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-01-23", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02885454" }, { "nct_id": "NCT01046058", "title": "TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "TMC435", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2010-01", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2013-10-14", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 3, "location_summary": "Anaheim, California • Orlando, Florida • San Antonio, Texas", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01046058" }, { "nct_id": "NCT02945020", "title": "A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Dabigatran etexilate mesylate", "type": "DRUG" }, { "name": "Odalasvir (ODV)", "type": "DRUG" }, { "name": "Simeprevir (SMV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 15, "start_date": "2016-11-10", "completion_date": "2017-01-20", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02945020" }, { "nct_id": "NCT03155893", "title": "A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ODV Placebo (Matching 25 mg ODV)", "type": "DRUG" }, { "name": "ODV Placebo (Matching 200 mg ODV)", "type": "DRUG" }, { "name": "ODV Placebo (Matching 125 mg ODV)", "type": "DRUG" }, { "name": "ODV Placebo (Matching 100 mg ODV)", "type": "DRUG" }, { "name": "SMV Placebo (Matching 150 mg SMV)", "type": "DRUG" }, { "name": "AL-335 Placebo (matching 1200 mg AL-335)", "type": "DRUG" }, { "name": "Moxifloxacin Placebo (matching 400 mg moxifloxacin)", "type": "DRUG" }, { "name": "ODV 25 mg", "type": "DRUG" }, { "name": "ODV 200 mg", "type": "DRUG" }, { "name": "ODV 125 mg", "type": "DRUG" }, { "name": "ODV 100 mg", "type": "DRUG" }, { "name": "SMV 150 mg", "type": "DRUG" }, { "name": "AL-335 1200 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 59, "start_date": "2017-05-12", "completion_date": "2017-10-27", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155893" }, { "nct_id": "NCT01628692", "title": "Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Simeprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2012-07", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-09-20T01:34:46.582Z", "location_count": 7, "location_summary": "San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01628692" } ] }